< Previous page ^ Table of Contents Next page >

First-stage Report of the Council on the development of accommodation for a new Cambridge Institute for Diabetes, Endocrinology, and Metabolism (CIDEM) at the Addenbrooke's Hospital Site

The COUNCIL beg leave to report to the University as follows:

1. In this Report the Council are seeking approval in principle for the development of accommodation for a new Cambridge Institute for Diabetes, Endocrinology, and Metabolism at the Addenbrooke's Hospital Site as set out below.

2. Over the past ten years the University of Cambridge School of Clinical Medicine has systematically built up its research strength in diabetes mellitus and related metabolic diseases, establishing a world-class grouping of highly collaborative researchers. Together these researchers provide an unprecedented opportunity for turning recent advances in the molecular, clinical, behavioural, and epidemiological sciences into real benefits for preventative medicine.

3. Research into diabetes mellitus and related metabolic diseases is necessarily collaborative and multidisciplinary. Establishing the Cambridge Institute for Diabetes, Endocrinology, and Metabolism (CIDEM) on the Addenbrooke's Hospital Site will draw together an exciting group of basic and clinical investigators in areas ranging from molecular biology and physiology to clinical medicine and epidemiology. The new facility will provide much needed laboratory space and room to accommodate additional clinical and laboratory research staff and principal investigators.

4. The research objectives of CIDEM will be to carry out three interconnected strands of scientific activity:

(a) Laboratory Science, generating new genetic, biochemical, and immunological information that will underpin the other activities of the Institute.
(b) Translational Research in Patients, occurring side by side with the ambulatory care activities of Addenbrooke's NHS Trust in the areas of diabetes, obesity, endocrinology, and metabolism.
(c) Prevention of Diabetes, the major long-term goal of the Institute and the particular focus of the Centre for Diabetes Prevention.

The expected outcomes of CIDEM are that it will:

(i) bring together in one facility the researchers and clinicians involved in diabetes and related metabolic disease research;
(ii) result in the recruitment of additional principal investigators and clinical research staff;
(iii) facilitate the rapid translation of research into clinical care;
(iv) attract major additional grant funding from research councils, charities, and industry for diabetes, endocrinology, and metabolism research;
(v) provide a unique educational resource;
(vi) lead to improvements in the treatment and prevention of Type 1 and Type 2 diabetes.

5. There is a strong desire and need to integrate this new facility with new accommodation that the Addenbrooke's NHS Trust are developing for Clinical Genetics and Diabetes out-patients. This will also include, for the Trust, an elective care unit incorporating theatres, day surgery units, and wards. The Trust are required to procure their facility through a Private Finance Initiative (PFI) route. To ensure the full integration of University and Trust facilities and the protection of the University's interests, the University has been represented in the negotiations and the development of the project.

6. It is anticipated that the Trust will procure the entire accommodation from a PFI provider and the University will then enter into a lease agreement with the Trust for the CIDEM space only. This agreement will provide for an up-front payment of rent, followed by unitary payments over the remaining period of the lease to cover maintenance, renewals, cleaning, security, and some equipment.

7. The current expectation is that the lease granted by the NHS Trust will be for a period expiring on 31 August 2061, thus aligning the University's interest in this building with its interests in other parts of the Addenbrooke's Site. The initial capital contribution will cover capital costs for the first 30 years, which is the period proposed for the PFI concession. Thereafter, the University will hold directly from the NHS Trust, and the expectation is that the rent will be a peppercorn. Discussions are continuing with the Trust and the possible PFI providers to resolve these issues before publication of a final Report.

8. The University's payment under the lease will include a contribution to the construction of a new out-patient department for diabetics within the building.

9. It is anticipated that the scheme will provide approximately 4,000 sq.m. (gross) space for the University as well as access to certain shared areas. The space will predominately contain wet and dry laboratory areas as well as accommodation for support services.

10. The budget for the University's contribution to the project is £15m of which £12.5m will be made as an up-front lease premium payment to the Trust on completion of the facility. The balance of the cost (£2.5m) covers the University's share of professional fees, infrastructure contributions, and allowances for the provision of car-parking spaces; this amount will be paid out over the period during which the building is constructed. The £15m funding will be made up from private donations to the School of Clinical Medicine, a donation from the Wolfson Foundation, and an amount of £4.5m drawn from the SRIF-2 funds allocated to the University. The running costs, including the unitary payments referred to in paragraph 5 above, amount to approximately £640,000 a year and will be met by the School of Clinical Medicine.

11. Further details of the project (including details of the legal arrangements which will apply at the end of the lease period) are due to be brought to the Planning and Resources Committee early in the Michaelmas Term 2003, and a further Report will be published later in the term. In the meantime the Council are seeking approval in principle for this new research facility.

12. The Council recommend:

That approval in principle be given for the University to procure the new research facility as proposed in this Report.

21 July 2003ALEC N. BROERS, Vice-ChancellorB. J. BRINDEDJAMES MATHESON
 S. H. ADELMANPETER GODDARDMARTIN REES
 SARAH AIREYD. A. GOODG. A. REID
 R. J. ANDERSONDAVID S. INGRAMM. SCHOFIELD
 RICHARD BARNESIAN LESLIELIBA TAUB
 JOHN BOYD  
Cambridge Institute for Diabetes, Endocrinology, and Metabolism (CIDEM) at the Addenbrooke's Hospital Site


< Previous page ^ Table of Contents Next page >

Cambridge University Reporter, 23 July 2003
Copyright © 2011 The Chancellor, Masters and Scholars of the University of Cambridge.